CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
Less than 1 min.Read

NST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense

November 18, 2020

NST002 Phase IIa Study: NeuroSense Therapeutics continues to report promising trends in their NST002 Phase IIa study, conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC). Following 9-months of treatment with PrimeC, preliminary trends seen at the interim analysis continue to show promise.

Dr. Shiran Zimri, Head of the Scientific Program at NeuroSense, states: “Following 9 months of treatment we see that the positive trend in patients’ respiratory function has continued, as indicated by higher than expected average FVC, correlating with the respiratory section of the ALSFRS-R. Additionally, a majority of the patients showed a reduced deterioration in ALSFRS-R score. Prof. Vivian Drory, the study’s Principal Investigator (PI), who sees the patients at each of their clinic visits, has voiced optimism from these results as they have exceeded her expectations”.

The study is set to be completed in January of 2021, following 12-months dosing. All patients participating in the study have already requested to continue with the treatment following its completion.

SourceNeuroSense Therapeutics

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

0
Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

0
Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

0
EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

0
The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

0
Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York, No. Carolina
United States
Phone Number: 1.561.316.3330